3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Lung Neoplasms
3
Neoplasm Metastasis
2
Cholangiocarcinoma
2
Biliary Tract Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Tertiary Lymphoid Structures
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Nasopharyngeal Carcinoma
1
Mesothelioma, Malignant
1
Mesothelioma
1
Gallbladder Neoplasms
1
Castration Resistant Prostate Cancer
1
Carcinoma, Transitional Cell
1
Camurati-Engelmann Syndrome
1
Breast Neoplasms
1
Interventions
Gemcitabine
83
Cisplatin
59
pembrolizumab
28
Paclitaxel
21
Nivolumab
21
Carboplatin
21
Cystectomy
20
Docetaxel
18
durvalumab
17
atezolizumab
17
Magnetic Resonance Spectroscopy
16
Specimen Handling
15
Radiotherapy
14
avelumab
13
Mitomycin
13
Sunitinib
12
Doxorubicin
12
Methotrexate
11
Fluorouracil
11
Vinblastine
10
Filgrastim
7
BCG Vaccine
7
Sorafenib
6
Ipilimumab
6
Immunoglobulin G
6
Disulfides
6
Biopsy
6
enfortumab vedotin
5
cabozantinib
5
Trastuzumab
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Urinary Bladder Neoplasms
×
bintrafusp alfa protein, human
×
Clear all
NCT04878250
2021-05-07
PEBBLE
Queen Mary University of London
Phase 2
Unknown
49 enrolled